KOL Views: How much of a threat is Pfizer's abrocitinib in atopic dermatitis?

Pfizer presented detailed Phase III JADE MONO-1 findings this week suggesting that abrocitinib looks more effective than Eli Lilly's rival JAK inhibitor baricitinib in patients with moderate-to-severe atopic dermatitis, albeit based on a cross-study comparison, and begging the question of whether it could potentially compete earlier in the treatment algorithm against the likes of Dupixent (dupilumab) from Regeneron Pharmaceuticals and Sanofi.

To provide FirstWord readers with rapid feedback on how abrocitinib and other JAK inhibitors may impact prescribing patterns for atopic dermatitis, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… what stands out about the new Phase III readout for abrocitinib; were you very, slightly or not at all impressed by abrocitinib's efficacy, including 44% of patients achieving 'clear' or 'almost clear' skin on the IGA scale and an EASI-75 response rate of 63% at 12 weeks; what side effects are you most concerned about with abrocitinib and how manageable is its safety profile; have any notable points of differentiation emerged among JAK inhibitors like abrocitinib, baricitinib and AbbVie's upadacitinib; does one JAK inhibitor look more attractive than the others in atopic dermatitis; could abrocitinib compete with Dupixent in patients who fail to respond to topical treatments and phototherapy; and are there any additional data that Pfizer could generate to boost abrocitinib's competitive profile against Dupixent?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the atopic dermatitis treatment landscape.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.